<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663518</url>
  </required_header>
  <id_info>
    <org_study_id>TTI-621-01</org_study_id>
    <nct_id>NCT02663518</nct_id>
  </id_info>
  <brief_title>A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trillium Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trillium Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory
      hematologic malignancies and selected solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies
      and selected solid tumors.

      TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the
      sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of
      human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from
      delivering an inhibitory &quot;do not eat&quot; (anti phagocytic) signal to macrophages.

      This trial will be conducted in 2 phases: Phase 1a (escalation phase) and Phase 1b (expansion
      phase).

      In the dose Escalation Phase (phase 1a), subjects with lymphoma will be enrolled in
      sequential dose cohorts to receive TTI-621 to characterize safety, tolerability,
      pharmacokinetics, and the maximum-tolerated dose (MTD).

      In the Expansion Phase (phase 1b), TTI-621 will be given to subjects with a variety of
      hematologic malignancies and selected solid tumors to further define safety and to
      characterize efficacy. In the Expansion Phase, the safety and efficacy of TTI-621 will also
      be assessed when it is given in combination with other anti-cancer drugs. The dose of TTI-621
      to be delivered in the Expansion Phase of the study may be increased or decreased based on
      the subject's tolerability and on the subject's response to treatment.

      Secondary objectives include further characterization of the pharmacokinetics,
      pharmacodynamics, and development of ADA; and to gain preliminary evidence of the anti-tumor
      activity of TTI-621 in subjects with a variety of hematologic malignancies and selected solid
      tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>42 months</time_frame>
    <description>Safety and tolerability of TTI-621 when given alone and in combination with other anti-cancer agents to subjects with a variety of hematologic malignancies and with selected solid tumors, and to evaluate the safety of a standardized intra-subject TTI-621 dose intensification schedule.</description>
  </primary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TTI-621 Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Escalation Phase will include multiple doses of TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indolent B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hodgkin Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Lymphocytic Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Lymphoblastic Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Myeloid Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloproliferative Neoplasms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral T-Cell Lymphoma (PTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621</intervention_name>
    <description>Monotherapy</description>
    <arm_group_label>TTI-621 Escalation Phase</arm_group_label>
    <arm_group_label>Indolent B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Aggressive B-Cell Lymphoma</arm_group_label>
    <arm_group_label>T-Cell Lymphoma</arm_group_label>
    <arm_group_label>Hodgkin Lymphoma</arm_group_label>
    <arm_group_label>Chronic Lymphocytic Leukemia</arm_group_label>
    <arm_group_label>Acute Lymphoblastic Leukemia</arm_group_label>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <arm_group_label>Acute Myeloid Leukemia</arm_group_label>
    <arm_group_label>Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>Myeloproliferative Neoplasms</arm_group_label>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_label>Peripheral T-Cell Lymphoma (PTCL)</arm_group_label>
    <other_name>SIRPαFc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 plus Rituximab</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Rituximab Combination</arm_group_label>
    <other_name>TTI-621 plus Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 plus Nivolumab</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Nivolumab Combination</arm_group_label>
    <other_name>TTI-621 plus Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced measurable malignancy

          2. Adequate hematologic status

          3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1
             prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will
             be considered a systemic therapy. Local radiation and topical agents are not systemic
             therapies.

          4. Adequate coagulation function

          5. Adequate hepatic function

          6. Adequate renal function

        Exclusion Criteria:

          1. Known, current central nervous system disease involvement or untreated brain
             metastases

          2. Allogeneic transplant within 30 days prior to the planned start of treatment or
             subjects with active graft-vs-host disease with the exception of Grade 1 skin
             involvement

          3. History of hemolytic anemia or bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penka Petrova, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Trillium Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meghan Irwin, EMBA, HBSc</last_name>
    <email>meghan@trilliumtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penka Petrova, PhD</last_name>
    <phone>416-595-0627</phone>
    <phone_ext>234</phone_ext>
    <email>penka@trilliumtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Hiett</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>80697</phone_ext>
      <email>jhiett@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Jaemee Bautista</last_name>
      <phone>626-218-3033</phone>
      <email>jbautista@coh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lyons</last_name>
      <phone>904-953-6826</phone>
      <email>Lyons.Christopher@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ansell</last_name>
      <phone>855-776-0015</phone>
      <email>ansell.stephen@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Tan</last_name>
      <phone>646-501-7869</phone>
      <email>Angela.Tan@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia Univeristy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Lichtenstein</last_name>
      <phone>212-326-5732</phone>
      <email>Rl2619@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Lesokhin</last_name>
      <phone>646-888-4593</phone>
      <email>lesokhia@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjali Advani</last_name>
      <email>ADVANIA@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Monette</last_name>
      <phone>503-494-9455</phone>
      <email>monette@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue McCann</last_name>
      <phone>412-864-3681</phone>
      <email>mccannsa@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cody Hammer</last_name>
      <email>chammer@seattlecca.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Villa</last_name>
      <phone>604-877-6000</phone>
      <email>dvilla@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nishita Parekh</last_name>
      <phone>416-581-7896</phone>
      <email>Nishita.Parekh@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clincancerres.aacrjournals.org/content/clincanres/early/2017/01/09/1078-0432.CCR-16-1700.full.pdf</url>
    <description>TTI-621: a novel innate immune checkpoint inhibitor</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-Cell</keyword>
  <keyword>CTCL</keyword>
  <keyword>PTCL</keyword>
  <keyword>ALL</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>TTI-621</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Cutaneous T-Cell Lymphoma</keyword>
  <keyword>Peripheral T-Cell Lymphoma</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>CD47</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

